W. Chou

Original article Adherence to dornase alfa treatment among commercially insured patients with cystic fibrosis

M. Broder, E. Chang, K. Villa, 2013 .

Adherence to dornase alfa treatment among commercially insured patients with cystic fibrosis

M. Broder, E. Chang, K. Villa, 2013, Journal of medical economics.

Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.

J. Stauffer, S. Nathan, W. Wuyts, 2019, Respiratory medicine.

Pirfenidone Reduces Respiratory‐related Hospitalizations in Idiopathic Pulmonary Fibrosis

H. Collard, J. Stauffer, K. Raimundo, 2017, American journal of respiratory and critical care medicine.

Risk of cardiovascular comorbidities in patients with idiopathic pulmonary fibrosis: Analysis of Medicare data

M. Broder, J. Stauffer, K. Raimundo, 2016 .

Omalizumab and malignancy: Interim results from the EXCELS study

M. Eisner, M. K. Miller, W. Chou, 2011 .

Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

J. Stauffer, S. Nathan, M. Glassberg, 2019, Advances in Therapy.